Xeljanz XR 11 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F1LYS
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $23,443
Award facts
- Contract value 100% obligated
- $23,442.58 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $23,442.58 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets (30-count units) on December 19, 2025, with completion scheduled for December 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999 through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare systems.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, demonstrates significant capability in federal medical procurement through its extensive portfolio of contract awards with the DLA Medical Supply Chain. The company supplies a comprehensive range of pharmaceutical products including brand-name and generic medications, vaccines, and specialized medical commodities across multiple therapeutic domains in support of the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. XELJANZ XR is a branded immunosuppressive medication used primarily for rheumatoid arthritis and other inflammatory conditions, reflecting AmerisourceBergen's role in delivering specialized pharmaceutical products critical to military and veteran healthcare operations.
Quick answers
Who was awarded contract SPE2DR26F1LYS?
SPE2DR26F1LYS was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 19, 2025.
How much is contract SPE2DR26F1LYS worth?
The government has obligated $23,443 on SPE2DR26F1LYS.
Is contract SPE2DR26F1LYS an order under another contract?
Yes. SPE2DR26F1LYS is a delivery order under SPE2DR25D2215, an indefinite delivery contract.
Was contract SPE2DR26F1LYS competed?
The extent of competition for SPE2DR26F1LYS was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award